Literature DB >> 6456890

Pharmacokinetics of cefoperazone: a review.

W A Craig, A U Gerber.   

Abstract

The pharmacokinetics of cefoperazone in normal subjects, and in patients with hepatic and renal dysfunction are reviewed. After intravenous administration of 2 g of cefoperazone, levels in serum ranged from 202 to 375 microgram/ml depending on the period of drug administration. After intramuscular injection of 2 g of cefoperazone, the mean peak serum level was 111 microgram/ml at 1.5 hours. At 12 hours after dosing, mean serum levels were still 2 to 4 microgram/ml. Cefoperazone was 90% bound to serum proteins. The apparent volume of distribution was 10 to 13L. The half-life of the drug varied from 1.6 to 2.4 hours; serum clearance was between 75 and 96 ml/min. Urinary excretion was rapid, but only 15 to 36% of the cefoperazone dose was recovered in the urine. Renal clearance ranged from 14 to 25 ml/min. Urine levels of cefoperazone in excess of 32 microgram/ml were maintained for at least 12 hours. Biliary levels of cefoperazone were many-fold higher than serum levels; peak bile concentrations from 675 to 6000 microgram/ml were obtained. Severe hepatic dysfunction was associated with a 2- to 4-fold increase in the half-life of cefoperazone. In patients with relatively complete biliary obstruction, over 90% of the dose was recovered in the urine. In contrast, the serum kinetics of cefoperazone were not significantly altered in patients with renal impairment. The human pharmacology of cefoperazone is similar to cephazolin in terms of serum concentrations, half-life, protein binding, and apparent volume of distribution, but markedly different in terms of biliary and renal excretion. Since biliary excretion is normally the primary route of cefoperazone elimination, dosage modification should only be required in the presence of severe biliary obstruction or concomitant renal and hepatic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456890     DOI: 10.2165/00003495-198100221-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Comparative pharmacokinetics of cefoperazone and cefotaxime.

Authors:  H Lode; B Kemmerich; P Koeppe; D Belmega; H Jendroschek
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

2.  Cefoperazone: absorption, excretion, distribution, and metabolism.

Authors:  K Shimizu
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

3.  Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats.

Authors:  L Balant; P Dayer; M Rudhardt; A F Allaz; J Fabre
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  [Pharmacokinetics of a new cephalosporin, cefoperazone].

Authors:  A F Allaz; P Dayer; J Fabre; M Rudhardt; L Balant
Journal:  Schweiz Med Wochenschr       Date:  1979-12-29
  5 in total
  11 in total

Review 1.  Pharmacokinetics of drugs in cystic fibrosis.

Authors:  M Spino
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.

Authors:  D P Reitberg; T J Whall; M Chung; D Blickens; H Swarz; J Arnold
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

3.  Alteration of hemostasis associated with cefoperazone treatment.

Authors:  K Andrassy; J Koderisch; S Fritz; H Bechtold; H Sonntag
Journal:  Infection       Date:  1986 Jan-Feb       Impact factor: 3.553

Review 4.  Classification of cephalosporins.

Authors:  J D Williams
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.

Authors:  C A Johnson; S W Zimmerman; D P Reitberg; T J Whall; J E Leggett; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

7.  In vitro susceptibility of Clostridium difficile isolates to cefotaxime, moxalactam, and cefoperazone.

Authors:  R A Greenfield; T A Kurzynski; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

8.  In vitro permeation of beta-lactam antibiotics across rat jejunum and its correlation with oral bioavailability in humans.

Authors:  Hiroshi Saitoh; Bruce J Aungst; Masashi Tohyama; Yuko Hatakeyama; Keiko Ohwada; Michiya Kobayashi; Hiroko Fujisaki; Katsumi Miyazaki
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

9.  Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.

Authors:  J I Schwartz; L E Jauregui; K A Bachmann; M E Martin; D P Reitberg
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

10.  Adsorptive cathodic stripping voltammetric determination of cefoperazone in bulk powder, pharmaceutical dosage forms, and human urine.

Authors:  Vu Dang Hoang; Dao Thi Huyen; Phan Hong Phuc
Journal:  J Anal Methods Chem       Date:  2013-09-10       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.